Table 3.
Comparison of changes in hemoglobin levels on users and non‐users of sodium–glucose cotransporter 2 inhibitors among propensity‐matched cohort (propensity score‐matched analyses)
| Mean hemoglobin levels (95% confidence interval) (g/L) † | Adjusted mean difference (95% confidence interval) | ||
|---|---|---|---|
| No SGLT2i | SGLT2i | ||
| Total | |||
| Baseline ‡ |
135 (131–140) (n = 98) |
135 (131–139) (n = 98) |
|
| 3 months § |
132 (129–134) (n = 81) |
136 (134–139) (n = 73) |
5.0 (1.0–8.0) |
| 6 months § |
131 (129–134) (n = 76) |
138 (135–140) (n = 80) |
7.0 (3.0–10.0) |
| 12 months § |
130 (128–132) (n = 84) |
137 (135–140) (n = 69) |
7.0 (4.0–11.0) |
| Those with estimated glomerular filtration rate ≤60 mL/min/1.73 m2 | |||
| Baseline ‡ |
131 (124–138) (n = 41) |
134 (127–141) (n = 39) |
|
| 3 months § |
128 (124–132) (n = 36) |
138 (132–140) (n = 32) |
7.6 (2.0–13.2) |
| 6 months § |
128 (124–132) (n = 34) |
138 (134–142) (n = 33) |
10.2 (4.1–16.3) |
| 12 months § |
127 (123–131) (n = 34) |
136 (132–141) (n = 31) |
8.9 (2.6–15.2) |
| Those with estimated glomerular filtration rate >60 mL/min/1.73 m2 | |||
| Baseline ‡ |
139 (133–144) (n = 57) |
135 (130–141) (n = 59) |
|
| 3 months § |
135 (131–138) (n = 45) |
137 (133–140) (n = 41) |
2.2 (−3.0 to 7.3) |
| 6 months § |
134 (130–137) (n = 42) |
138 (134–141) (n = 47) |
3.8 (−0.9 to 8.5) |
| 12 months § |
132 (130–135) (n = 50) |
138 (135–141) (n = 38) |
5.6 (1.5–9.7) |
The number of available data are shown in parenthesis.
The data at 3, 6, and 12 months were adjusted for baseline hemoglobin levels.
For users of sodium–glucose cotransporter 2 inhibitors (SGLT2i), hemoglobin levels before and the closest to the initiation of SGLT2i were used, and for non‐users of SGLT2i, the first measurement of hemoglobin levels during the study period were used.
For users of SGLT2i, the time from initiation of SGLT2i was used and for non‐users of SGLT2i, the time from the first measurement of hemoglobin levels was used. The data within 1 month were allowed.